53 completed, 23 terminated, 9 recruiting, 9 unknown. 67 Phase 2, 24 Phase 3, 18 Phase 1.
Follow Navelbine: new trials by email Literature Review of Navelbine trials Research Report on Navelbine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine - Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Michael Spinner, MD | 38 | 2026-08-18 | 2026-10-20 |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Rhabdomyosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 342 | 2026-07-14 | 2026-08-25 |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer Evorpacept (ALX148), Trastuzumab, Paclitaxel - Breast Cancer, Metastatic | Phase 2 | Recruiting | ALX Oncology Inc. | 120 | 2025-12-10 | 2026-09-25 |
| A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel - Carcinoma, Non-Small -Cell Lung | Phase 3 | Recruiting | Maia Biotechnology | 300 | 2025-12-08 | 2026-01-12 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer Organoid-guided treatment, Taxane, Capecitabine - HER2-negative Breast Cancer, Advanced Breast Cancer | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 252 | 2024-10-01 | 2024-11-25 |
| To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment Vinorelbine Tartrate Oral - Advanced Breast Cancer | Active not recruiting | Pierre Fabre Medicament | 368 | 2024-09-10 | 2026-07-02 | |
| FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer FDA018-ADC, Eribulin, Capecitabine - Triple Negative Breast Cancer | Phase 3 | Active not recruiting | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 350 | 2024-08-09 | 2026-01-22 |
| Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease Vincristine, Dactinomycin, Cyclophosphamide - Rhabdomyosarcoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 135 | 2024-03-13 | 2026-06-15 |
| Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer Organoid-guided personalized treatment, Gemcitabine, Capecitabine - Breast Cancer, Refractory Breast Carcinoma | Phase 3 | Recruiting | Sun Yat-sen University | 302 | 2024-01-15 | 2024-02-20 |
| Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer Tucatinib, Trastuzumab, Vinorelbine - HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma | Phase 2 | Terminated | Spanish Breast Cancer Research Group | 13 | 2023-03-08 | 2025-12-10 |
| A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma | Phase 3 | Active not recruiting | Children's Oncology Group | 113 | 2021-09-14 | 2026-07-30 |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) Trastuzumab, Alpelisib, Fulvestrant - Advanced Breast Cancer | Phase 3 | Terminated | Spanish Breast Cancer Research Group | 27 | 2021-09-14 | 2026-10-15 |
| Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer Navelbine, Docetaxel - Breast Cancer | Phase 3 | Unknown | Zhejiang Cancer Hospital | 50 | 2021-03-01 | 2020-12-14 |
| Evolutionary Therapy for Rhabdomyosarcoma Vincristine, Cyclophosphamide, Vinorelbine - Rhabdomyosarcoma | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2020-12-29 | 2025-11-26 |
| Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral Product - Metastatic Breast Cancer | Phase 3 | Active not recruiting | Gilead Sciences | 331 | 2020-11-23 | 2026-02-09 |
| A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 RC48-ADC, Paclitaxel Injection, Docetaxel Injection - Breast Cancer | Phase 3 | Recruiting | RemeGen Co., Ltd. | 366 | 2020-09-29 | 2026-09-23 |
| Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. Disulfiram, Vinorelbin, Cisplatin - Metastatic Breast Cancer | Phase 2 | Withdrawn | National Cancer Institute, Slovakia | 2020-01-01 | 2023-10-06 | |
| A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer Alectnib, Cisplatin, Vinorelbine - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Hoffmann-La Roche | 257 | 2018-08-16 | 2026-10-14 |
| Vinorelbine in Advanced BRAF-like Colon Cancer Vinorelbine Tartrate - Colon Cancer | Phase 2 | Completed | The Netherlands Cancer Institute | 1 | 2018-03-01 | 2025-08-03 |
Showing 20 of 103. Sign in to see all of them.
Breast Neoplasms (44) · Carcinoma, Non-Small-Cell Lung (25) · Lung Neoplasms (9) · Hodgkin Disease (6) · Lymphoma (5) · Neoplasm Metastasis (5) · Neoplasms (5) · Rhabdomyosarcoma (5) · Recurrence (3) · Sarcoma (3) · Triple Negative Breast Neoplasms (3) · Melanoma (2) · Multiple Myeloma (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1)
Hellenic Oncology Research Group (8) · Spanish Breast Cancer Research Group (4) · Children's Oncology Group (3) · Dana-Farber Cancer Institute (3) · University of Washington (3) · Armando Santoro, MD (2) · Dartmouth-Hitchcock Medical Center (2) · ETOP IBCSG Partners Foundation (2) · Gilead Sciences (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · National Cancer Institute (NCI) (2) · Northwestern University (2) · Pierre Fabre Medicament (2) · SWOG Cancer Research Network (2) · Stanford University (2)
United States (46) · France (12) · Italy (12) · Spain (12) · Greece (11) · China (10) · Canada (8) · United Kingdom (7) · Germany (6) · Switzerland (6) · Netherlands (5) · Australia (4) · Denmark (3) · Puerto Rico (3) · South Korea (3)
Dimitris Mavrudis, MD (3) · Armando Santoro, MD (2) · Eric Winer, MD (2) · Julie R. Gralow, M.D. (2) · Vassilis Georgoulias, MD (2) · A Bardelli, Prof (1) · A Cervantes, Prof (1) · Aimin Zang (1) · Airong Wang (1) · Alberto Pappo, MD (1) · Alessandra Curioni-Fontecedro, MD (1) · Alessandro Bertolini, MD (1) · Alessandro Del Conte, MD (1)
PMID 15073859, PMID 15246197, PMID 15297403, PMID 17329192, PMID 19224841, PMID 20863157, PMID 23718900, PMID 24678902, PMID 25662596, PMID 27135612, PMID 27382096, PMID 27491498, PMID 27677906, PMID 28410809, PMID 29119276, PMID 29129443, PMID 29938395, PMID 31513481, PMID 31538815, PMID 31935284, PMID 33070624, PMID 33093337, PMID 33453470, PMID 33882206, PMID 33892407, PMID 34280355, PMID 34347542, PMID 34467774, PMID 34543871, PMID 34994617, PMID 35292802, PMID 35465733, PMID 35545724, PMID 35706488, PMID 35728046, PMID 37440239, PMID 37561451, PMID 38422473, PMID 38598794, PMID 38664404, PMID 39324726, PMID 39354196, PMID 39854662, PMID 40421698, PMID 40657894, PMID 41217067, PMID 41666849, PMID 41698326, PMID 41838385, PMID 41996761
2016 (3), 2017 (3), U10CA032102 (2), U10CA180886 (2), 2005 (1), 2015 (1), K23AI052413 (1), P30CA023108 (1), P30CA036727 (1), P30CA093373 (1), P50CA058223 (1), R21CA105837 (1), U10CA021115 (1), U10CA027469 (1), U10CA098543 (1)